|
HK137593A
|
|
Physiological means of enhancing transdermal delivery of drugs
|
|
SG132293G
|
|
Physiological means of enhancing transdermal delivery of drugs
|
|
HK16093A
|
|
Controlled release potassium chloride
|
|
HK17990A
|
|
Trinitroglycerol sustained release vehicles and preparation therefrom
|
|
US4983396A
|
|
Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol
|
|
DK493887A
|
|
Buccal composition
|
|
EP0293503A1
|
|
Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations
|
|
ES8708186A1
|
|
Adhesive transdermal drug delivery systems
|
|
IE862841L
|
|
Blocking antigen-induced allergic responses
|
|
EP0245366A1
|
|
Method and composition for blocking antigen-induced allergic responses
|
|
WO8701282A2
|
|
Method and composition for providing sustained opioid antagonism
|
|
EP0231266A1
|
|
Composition for the treatment of chronic obstructive pulmonary disease
|
|
DK128486D0
|
|
Adhesive transdermal dual-layer dosing system and corresponding adhesive transdermal dosing layer and method for the manufacture of such a layer
|
|
CA1270765A
|
|
Controlled release potassium chloride
|
|
IE860433L
|
|
Controlled release potassium chloride
|
|
US4722726A
|
|
Method and apparatus for iontophoretic drug delivery
|
|
US4755386A
|
|
Buccal formulation
|
|
US4764381A
|
|
Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
|
|
US4689213A
|
|
Method and composition for treating bronchospastic airway diseases
|
|
EP0198034A1
|
|
Physiological means of enhancing transdermal delivery of drugs.
|
